Last reviewed · How we verify
propiverine hydrochloride
Propiverine hydrochloride, marketed by APOGEPHA Arzneimittel GmbH, is an established drug in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | propiverine hydrochloride |
|---|---|
| Also known as | Mictonorm, Propierine Hydrochloride Extended-Release Capsule, Mictonorm UNO 45, Detrunorm XL 45, BUP-4 |
| Sponsor | APOGEPHA Arzneimittel GmbH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Overactive Bladder With Anticholinergic Agents
- Uroflowmetry and Nocturnal Enuresis
- Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. (PHASE4)
- Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients (NA)
- Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis (NA)
- Behavioural Therapy With Checklist for Overactive Bladder (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- propiverine hydrochloride CI brief — competitive landscape report
- propiverine hydrochloride updates RSS · CI watch RSS
- APOGEPHA Arzneimittel GmbH portfolio CI